Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Strategies for Rapid Build of HIV Protective Barriers in Yunnan
NCT03852849Unknown
- Sponsor
- CNAIDS
- Start
- Mar 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of efavirenz in human immunodeficiency virus infection (HIV) (3 arms), sponsored by CNAIDS. Primary endpoint: Viral suppression of HIV-infected patients at 12 months. Status: unknown.
02
Drugs
efavirenz
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03852849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03852849.